Shigenobu Yano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shigenobu Yano has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Hiromi Kataoka
Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
30 shared publications Takashi Joh
27 shared publications- Mamoru Tanaka
Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan
26 shared publications - Noriyuki Hayashi
Faculty of Engineering, University of Miyazaki
26 shared publications - Atsushi Narumi
Graduate School of Organic Materials Science, Yamagata University, 4-3-16 Jonan, Yonezawa, Yamagata 992-8510, Japan
17 shared publications - Akihiro Nomoto
QST Hospital, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba, 263-8555, Japan
16 shared publications
Latest Publications
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Maltotriose Conjugation to a Chlorin Derivative Enhances the Antitumor Effects of Photodynamic Therapy in Peritoneal Dissemination of Pancreatic Cancer
Images of representative abdominal skin of mice from each group.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Maltotriose Conjugation to a Chlorin Derivative Enhances the Antitumor Effects of Photodynamic Therapy in Peritoneal Dissemination of Pancreatic Cancer
Images of representative abdominal skin of mice from each group.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Maltotriose Conjugation to a Chlorin Derivative Enhances the Antitumor Effects of Photodynamic Therapy in Peritoneal Dissemination of Pancreatic Cancer
Correlation between the fluorescence intensities and the dose of Mal3-chlorin or the number of cells.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Maltotriose Conjugation to a Chlorin Derivative Enhances the Antitumor Effects of Photodynamic Therapy in Peritoneal Dissemination of Pancreatic Cancer
Correlation between the fluorescence intensities and the dose of Mal3-chlorin or the number of cells.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure Legends from Maltotriose Conjugation to a Chlorin Derivative Enhances the Antitumor Effects of Photodynamic Therapy in Peritoneal Dissemination of Pancreatic Cancer
Supplementary Figure S1: Cell viability in pancreatic cancer cells treated by talaporfin with or without irradiation. Supplementary Figure S2: The luciferase luminescence intensities in AsPC1/luc cells treated by PDT with talaporfin or Mal3-chlorin. Cells were treated with talaporfin (1-16 μM) or Mal3-chlorin (0.1-2 μM) at 37{degree sign}C for 4 h, and then irradiated. After incubation for 24 h, cells were incubated for a short time at 37{degree sign}C with D-luciferin (150 μg/mL, Wako, Ltd.) in media. Luminescence was measured using a Lu mat LB 9507 instrument (EG&G BERTHOLD) and the data were normalized against the average value of non-treated cells. Values are means {plus minus} SD, n = 4 in each. Supplementary Figure S3: Average body weight transitions of mice during the experiment. Values are means {plus minus} SD, n = 7 in each. Supplementary Figure S4: Images of representative abdominal skin of mice from each group. Representative imaging of abdominal skin from mice at day 1, 8, and 15 on the treatment regimen as shown in Figure 4A: Control mice (left panel), talaporfin-mediated PDT mice (middle panel), and Mal3-chlorin-mediated PDT mice (right panel). Supplementary Figure S5: Involvement of GLUT1 in the uptake of Mal3-chlorin into pancreatic cancer cells. AsPC1/luc or BxPC3/luc cells were seeded into 96-well culture plates at a concentration of 5 Ã- 103 cells/well and incubated overnight. Cells were subsequently treated with WZB117 (0.1-30 μM; EMD Chemicals, San Diego, CA, USA), which is a pharmacological GLUT1 inhibitor. After incubation for 24 h, cells were incubated for 4 h with Mal3-chlorin (1 μM) and WZB117 (0.1-30 μM), and levels of specific fluorescence were measured by Spectrafluor Plus (excitation; 405 nm, emission; 660 nm). The data were normalized against the average value of non-treated cells. Values are means {plus minus} SD, n = 6 in each. Supplementary Figure S6: Correlation between the fluorescence intensities and the dose of Mal3-chlorin or the number of cells. AsPC1/luc cells were seeded into 96-well culture plates at a concentration of 1 Ã- 103 - 8 Ã- 103 cells/well and incubated overnight. Cells were subsequently incubated for 4 h with Mal3-chlorin (0.05-2 μM) and then fluorescence levels were measured using a Spectrafluor Plus (excitation; 405 nm, emission; 660 nm). Values are means {plus minus} SD, n = 6 in each.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure Legends from Maltotriose Conjugation to a Chlorin Derivative Enhances the Antitumor Effects of Photodynamic Therapy in Peritoneal Dissemination of Pancreatic Cancer
Supplementary Figure S1: Cell viability in pancreatic cancer cells treated by talaporfin with or without irradiation. Supplementary Figure S2: The luciferase luminescence intensities in AsPC1/luc cells treated by PDT with talaporfin or Mal3-chlorin. Cells were treated with talaporfin (1-16 μM) or Mal3-chlorin (0.1-2 μM) at 37{degree sign}C for 4 h, and then irradiated. After incubation for 24 h, cells were incubated for a short time at 37{degree sign}C with D-luciferin (150 μg/mL, Wako, Ltd.) in media. Luminescence was measured using a Lu mat LB 9507 instrument (EG&G BERTHOLD) and the data were normalized against the average value of non-treated cells. Values are means {plus minus} SD, n = 4 in each. Supplementary Figure S3: Average body weight transitions of mice during the experiment. Values are means {plus minus} SD, n = 7 in each. Supplementary Figure S4: Images of representative abdominal skin of mice from each group. Representative imaging of abdominal skin from mice at day 1, 8, and 15 on the treatment regimen as shown in Figure 4A: Control mice (left panel), talaporfin-mediated PDT mice (middle panel), and Mal3-chlorin-mediated PDT mice (right panel). Supplementary Figure S5: Involvement of GLUT1 in the uptake of Mal3-chlorin into pancreatic cancer cells. AsPC1/luc or BxPC3/luc cells were seeded into 96-well culture plates at a concentration of 5 Ã- 103 cells/well and incubated overnight. Cells were subsequently treated with WZB117 (0.1-30 μM; EMD Chemicals, San Diego, CA, USA), which is a pharmacological GLUT1 inhibitor. After incubation for 24 h, cells were incubated for 4 h with Mal3-chlorin (1 μM) and WZB117 (0.1-30 μM), and levels of specific fluorescence were measured by Spectrafluor Plus (excitation; 405 nm, emission; 660 nm). The data were normalized against the average value of non-treated cells. Values are means {plus minus} SD, n = 6 in each. Supplementary Figure S6: Correlation between the fluorescence intensities and the dose of Mal3-chlorin or the number of cells. AsPC1/luc cells were seeded into 96-well culture plates at a concentration of 1 Ã- 103 - 8 Ã- 103 cells/well and incubated overnight. Cells were subsequently incubated for 4 h with Mal3-chlorin (0.05-2 μM) and then fluorescence levels were measured using a Spectrafluor Plus (excitation; 405 nm, emission; 660 nm). Values are means {plus minus} SD, n = 6 in each.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Maltotriose Conjugation to a Chlorin Derivative Enhances the Antitumor Effects of Photodynamic Therapy in Peritoneal Dissemination of Pancreatic Cancer
The luciferase luminescence intensities in AsPC1/luc cells treated by PDT with talaporfin or Mal3-chlorin.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Maltotriose Conjugation to a Chlorin Derivative Enhances the Antitumor Effects of Photodynamic Therapy in Peritoneal Dissemination of Pancreatic Cancer
The luciferase luminescence intensities in AsPC1/luc cells treated by PDT with talaporfin or Mal3-chlorin.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Maltotriose Conjugation to a Chlorin Derivative Enhances the Antitumor Effects of Photodynamic Therapy in Peritoneal Dissemination of Pancreatic Cancer
Correlation between the fluorescence intensities and the dose of Mal3-chlorin or the number of cells.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Maltotriose Conjugation to a Chlorin Derivative Enhances the Antitumor Effects of Photodynamic Therapy in Peritoneal Dissemination of Pancreatic Cancer
Correlation between the fluorescence intensities and the dose of Mal3-chlorin or the number of cells.